Sharp Biomedical closed a pre-seed funding round led by gener8tor 1889, with participation from several physician angel investors. The Fargo, North Dakota-based medical device company is developing streamlined toolsets and implants designed for outpatient spine procedures targeting patients with early-to-mid-stage chronic pain.
The new capital will fully fund the development and testing pathway for Sharp Biomedical’s first purpose-built toolset and implant system.
The company is designing the technology specifically for outpatient pain clinic workflows, with the goal of giving physicians an additional treatment option before patients progress to later-stage spinal care.
Sharp Biomedical is focusing on manual procedures that can be performed in outpatient settings without requiring major capital investments or extensive infrastructure upgrades.
The company said its approach is intended to expand access to interventional spine care by enabling more procedures to be performed directly in local clinics.
Sharp Biomedical is positioning its strategy as complementary to the industry’s growing use of robotics and other complex technologies for late-stage spinal treatment.
The company believes a significant unmet need remains earlier in the care continuum, where simpler procedures may allow physicians to intervene sooner.
With the pre-seed round completed, Sharp Biomedical plans to move ahead with testing protocols and continued physician input as it works toward future regulatory milestones.
The company is also preparing for the eventual commercial launch of its flagship device.
Sharp Biomedical designs its products around physician feedback and aims to reduce reliance on large hospital infrastructure, robotics, and prolonged operating times.
Gener8tor 1889, which led the round, is a North Dakota-focused venture capital fund operated by gener8tor.
KEY QUOTES:
“While the industry is rightfully focused on remarkable advancements in robotics and complex technologies for late-stage spinal care, we see a massive unmet need earlier in the care continuum. We are thrilled to partner with gener8tor 1889 and our angel investors to finalize our development. This pre-seed funding allows us to empower physicians with simple, safe, and reliable procedures—giving clinics advanced intervention capabilities without the burden of massive capital demands.”
Dan Newman, Founder and CEO of Sharp Biomedical
“Dan is an extremely impressive startup founder, and we have built a huge amount of conviction in him and the entire Sharp Biomedical team. Their mission to democratize access to spine care by empowering outpatient clinics with fast, safe, and reliable toolsets is a breath of fresh air in a highly complex industry. We look forward to both the profound impact this technology will have on patient care, along with their continued commitment to growing the North Dakota biotech ecosystem.”
Ben Stanley, Principal of gener8tor 1889
“I’m excited to partner with Sharp Biomedical as they fill a vital gap in the market. What sets Sharp apart is their intelligent design process, rooted in true collaborative input from physicians to directly address real clinical needs. This partnership will allow us to intervene earlier in the care continuum and offer definitive relief right in the outpatient setting, and their talented team is exceptionally well-positioned to drive these advancements.”
Dr. Danny Neuman, Interventional Pain Specialist, Medical Staff President at Ascentist Healthcare, and Advisor to Sharp Biomedical
